medigraphic.com
ISSN 2007-6053 (Impreso)
Órgano oficial de difusión de los Hospitales Regionales de Alta Especialidad (HRAE)

2014, Número 1

<< Anterior Siguiente >>

Evid Med Invest Salud 2014; 7 (1)


Derrame paraneumónico y empiema. A propósito de una revisión integral

Cortés-Telles A, Laguna BP, Vázquez-Callejas A

Idioma: Español
Referencias bibliográficas: 52
Paginas: 24-33
Archivo PDF: 347.05 Kb.


RESUMEN

En años recientes se ha incrementado el número de casos confirmados de derrame paraneumónico y/o empiema. El desenlace de la enfermedad tiene asociación con el tiempo que transcurre entre el comienzo de los síntomas y la evaluación médica inicial. Dicha transición epidemiológica ha incrementado el conocimiento general de la fisiopatología; del mismo modo, se han revolucionado las diferentes rutas del abordaje diagnóstico y tratamiento con enfoque sobre el uso adecuado de las estrategias terapéuticas disponibles. Esta revisión tiene como objetivo proporcionar un panorama global de la enfermedad con base en la mejor evidencia disponible para orientar sobre las decisiones de la práctica clínica cotidiana.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bouros D, Plataki M, Antoniou KM. Parapneumonic effusion and empyema: best therapeutic approach. Monaldi Arch Chest Dis. 2001; 56: 144-148.

  2. Hamm H, Light RW. Parapneumonic effusion and empyema. Eur Respir J. 1997; 10: 1150-1156.

  3. Farjah F, Symons RG, Krishnadasan B, Wood DE, Flum DR. Management of pleural space infections: a population-based analysis. J Thorac Cardiovasc Surg. 2007; 133: 346-351.

  4. Finley C, Clifton J, Fitzgerald JM, Yee J. Empyema: an increasing concern in Canada. Can Respir J. 2008; 15: 85-89.

  5. Grijalva CG, Zhu Y, Nuorti JP, Griffin MR. Emergence of parapneumonic empyema in the USA. Thorax. 2011; 66: 663-668.

  6. Sahn SA. Diagnosis and management of parapneumonic effusions and empyema. Clin Infect Dis. 2007; 45: 1480-1486.

  7. Singh G, Pitoyo CW, Nasir AU, Rumende CM, Amin Z. Update on the role of intrapleural fibrinolytic therapy in the management of complicated parapneumonic effusions and empyema. Acta Med Indones. 2012; 44: 258-264.

  8. Sosa-Juárez A, García-Sancho C, Sánchez-Hernández JD, Jaime-Capetillo ME, Fernández-Plata R, Martínez-Briseño D et al. Epidemiología del derrame pleural en el INER, 2011-2012. Neumol Cir Torax. 2013; 72: 136-141.

  9. Macias J, Quintana M. Causas y prevalencia del derrame pleural en el Hospital General Naval de Alta Especialidad. Med Int Mex 2012; 28 (3): 240-243.

  10. Chalmers JD, Singanayagam A, Murray MP, Scally C, Fawzi A, Hill AT. Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. Thorax. 2009; 64: 592-597.

  11. Falguera M, Carratala J, Bielsa S, Garcia-Vidal C, Ruiz-Gonzalez A, Chica I et al. Predictive factors, microbiology and outcome of patients with parapneumonic effusion. Eur Respir J. 2011; 38: 1173-1179.

  12. Rodriguez Suarez P, Freixinet Gilart J, Hernandez Perez JM, Hussein Serhal M, Lopez Artalejo A. Treatment of complicated parapneumonic pleural effusion and pleural parapneumonic empyema. Med Sci Monit. 2012; 18 (7): CR443-449.

  13. Wrightson JM, Fysh E, Maskell NA, Lee YC. Risk reduction in pleural procedures: sonography, simulation and supervision. Curr Opin Pulm Med. 2010; 16: 340-350.

  14. Rothschild JM, Landrigan CP, Cronin JW, Kaushal R, Lockley SW, Burdick E et al. The critical care safety study: The incidence and nature of adverse events and serious medical errors in intensive care. Crit Care Med. 2005; 33: 1694-1700.

  15. Herrera-Kiengelher L, Baez-Saldana R, Salas-Hernandez J, Avalos-Bracho A, Perez-Padilla R, Torre-Bouscoulet L. Frequency of adverse events and mortality in patients with pleural empyema in a public referral hospital in Mexico City. Int J Tuberc Lung Dis. 2010; 14: 1187-1192.

  16. Aiyappan V, Munawar A, Thien F. Junior doctor training in pleural procedures: a quality survey. Intern Med J. 2013; 43: 96-100.

  17. Alfageme I, Munoz F, Pena N, Umbria S. Empyema of the thorax in adults. Etiology, microbiologic findings, and management. Chest. 1993; 103: 839-843.

  18. Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, Miller R et al. UK. Controlled trial of intrapleural streptokinase for pleural infection. N Eng J Med. 2005; 352: 865-874.

  19. Maskell NA, Batt S, Hedley EL, Davies CW, Gillespie SH, Davies RJ. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am J Respir Crit Care Med. 2006; 174: 817-823.

  20. Davies HE, Davies RJ, Davies CW, Group BTSPDG. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010; 65 Suppl 2: ii41-53.

  21. Mandal AK, Thadepalli H, Mandal AK, Chettipally U. Outcome of primary empyema thoracis: therapeutic and microbiologic aspects. Ann Thorac Surg. 1998; 66: 1782-1786.

  22. Rahman NM, Chapman SJ, Davies RJ. The approach to the patient with a parapneumonic effusion. Clin Chest Med. 2006; 27: 253-266.

  23. Ko SC, Chen KY, Hsueh PR, Luh KT, Yang PC. Fungal empyema thoracis: an emerging clinical entity. Chest. 2000; 117: 1672-1678.

  24. Porcel JM, Light RW. Pleural effusions. Dis Mon. 2013; 59: 29-57.

  25. Light RW. Pleural effusions. Med Clin North Am. 2011; 95: 1055-1070.

  26. Grove CS, Lee YC. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med. 2002; 8: 294-301.

  27. Girdhar A, Shujaat A, Bajwa A. Management of infectious processes of the pleural space: a review. Pulm Med. 2012; 2012: 816502.

  28. Koegelenberg CF, Diacon AH, Bolliger CT. Parapneumonic pleural effusion and empyema. Respiration. 2008; 75: 241-250.

  29. Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med. 1980; 69: 507-512.

  30. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009; 64 Suppl 3: iii1-55.

  31. Sahn SA. Management of complicated parapneumonic effusions. Am Rev Respir Dis. 1993; 148: 813-817.

  32. Bhatnagar R, Maskell NA. Treatment of complicated pleural effusions in 2013. Clin Chest Med. 2013; 34: 47-62.

  33. Tobin CL, Lee YC. Pleural infection: what we need to know but don’t. Curr Opin Pulm Med. 2012; 18: 321-325.

  34. Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Eng J Med. 2011; 365: 518-526.

  35. Menzies SM, Rahman NM, Wrightson JM, Davies HE, Shorten R, Gillespie SH et al. Blood culture bottle culture of pleural fluid in pleural infection. Thorax. 2011; 66: 658-662.

  36. Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc. 2006; 3: 75-80.

  37. Hooper C, Lee YC, Maskell N, Group BTSPG. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010; 65 (Suppl 2): ii4-17.

  38. Brixey AG, Luo Y, Skouras V, Awdankiewicz A, Light RW. The efficacy of chest radiographs in detecting parapneumonic effusions. Respirology. 2011; 16: 1000-1004.

  39. Kearney SE, Davies CW, Davies RJ, Gleeson FV. Computed tomography and ultrasound in parapneumonic effusions and empyema. Clin Radiol. 2000; 55: 542-547.

  40. Shohet I, Yellin A, Meyerovitch J, Rubinstein E. Pharmacokinetics and therapeutic efficacy of gentamicin in an experimental pleural empyema rabbit model. Antimicrob Agents Chemother. 1987; 31: 982-985.

  41. Thys JP, Vanderhoeft P, Herchuelz A, Bergmann P, Yourassowsky E. Penetration of aminoglycosides in uninfected pleural exudates and in pleural empyemas. Chest. 1988; 93: 530-532.

  42. Bartlett JG, Finegold SM. Anaerobic infections of the lung and pleural space. Am Rev Respir Dis. 1974; 110: 56-77.

  43. Heffner JE, Brown LK, Barbieri C, DeLeo JM. Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis. Am J Respir Crit Care Med. 1995; 151: 1700-1708.

  44. Taryle DA, Potts DE, Sahn SA. The incidence and clinical correlates of parapneumonic effusions in pneumococcal pneumonia. Chest. 1978; 74: 170-173.

  45. Light RW. Pleural controversy: optimal chest tube size for drainage. Respirology. 2011; 16: 244-248.

  46. Liu YH, Lin YC, Liang SJ, Tu CY, Chen CH, Chen HJ et al. Ultrasound-guided pigtail catheters for drainage of various pleural diseases. Am J Emerg Med. 2010; 28: 915-921.

  47. Rahman NM, Maskell NA, Davies CW, Hedley EL, Nunn AJ, Gleeson FV et al. The relationship between chest tube size and clinical outcome in pleural infection. Chest. 2010; 137: 536-543.

  48. Tokuda Y, Matsushima D, Stein GH, Miyagi S. Intrapleural fibrinolytic agents for empyema and complicated parapneumonic effusions: a meta-analysis. Chest. 2006; 129: 783-790.

  49. Cameron R, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev. 2008; 12: CD002312.

  50. Janda S, Swiston J. Intrapleural fibrinolytic therapy for treatment of adult parapneumonic effusions and empyemas: a systematic review and meta-analysis. Chest. 2012; 142: 401-411.

  51. Chambers A, Routledge T, Dunning J, Scarci M. Is video-assisted thoracoscopic surgical decortication superior to open surgery in the management of adults with primary empyema? Interac Cardiovasc Thorac Surg. 2010; 11: 171-177.

  52. Luh SP, Chou MC, Wang LS, Chen JY, Tsai TP. Video-assisted thoracoscopic surgery in the treatment of complicated parapneumonic effusions or empyemas: outcome of 234 patients. Chest. 2005; 127: 1427-1432.




2020     |     www.medigraphic.com